Compare Main Street Capital Corporation (MAIN) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Neurocrine Biosciences Inc — how do they compare? Main Street Capital Corporation trades at $54.5 (market cap $5.09B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.8× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 5.84% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 88 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MAIN | NBIX | |
|---|---|---|
Market Cap | $5.09B | $14.36B |
Volume | 524,060 | 1,237,180 |
Sector | Financials | Health |
52-Week High | $64.60 | $185.50 |
52-Week Low | $49.63 | $123.10 |
Typical Hold Time | 88 Days | 23 Days |
Enterprise Value | $7.54B | $14.37B |
Dividend Yield | 5.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAIN trades at $54.18, down 1.08% on the day, with a bearish technical signal from moving averages and oscillators. The company reported revenue of $592 million and net income of $493 million for 2025, with a net income margin of 83.36%. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1 2026. Analyst consensus is a Hold with a $58.33 price target, indicating modest upside potential.
Outlook: MAIN offers a stable dividend history and strong profitability, but faces headwinds from softening revenue projections for 2026 and negative operating cash flow. Risks include earnings volatility and high valuation multiples. The stock presents a cautious opportunity for income-focused investors, balanced by near-term fundamental pressures.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
